Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LB-100 |
Trade Name | |
Synonyms | LB100|LB 100 |
Drug Descriptions |
LB-100 is a small molecule that inhibits PP2A activity, resulting in increased sensitivity of tumor cells to DNA damaging agents, including chemotherapy and radiotherapy (PMID: 25376608, PMID: 31935881, PMID: 30679389, PMID: 32342332). |
DrugClasses | PP2A Inhibitor 2 |
CAS Registry Number | 1632032-53-1 |
NCIT ID | C106430 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + Carboplatin + Etoposide + LB-100 | Atezolizumab Carboplatin Etoposide LB-100 | 0 | 1 |
Atezolizumab + LB-100 | Atezolizumab LB-100 | 0 | 2 |
Ceralasertib + LB-100 | Ceralasertib LB-100 | 0 | 0 |
Cisplatin + LB-100 | Cisplatin LB-100 | 2 | 0 |
Docetaxel + LB-100 | Docetaxel LB-100 | 0 | 1 |
Dostarlimab-gxly + LB-100 | Dostarlimab-gxly LB-100 | 0 | 1 |
Doxorubicin + LB-100 | Doxorubicin LB-100 | 0 | 1 |
LB-100 | LB-100 | 0 | 2 |
LB-100 + LY2603618 | LB-100 LY2603618 | 0 | 0 |